Brief: Island Pharmaceuticals Acquires Grant Research Support
07/07/2023 02:01
July 7 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* ACQUIRED GRANT RESEARCH SUPPORT FOR PLANNED ISLA-101 PHASE
2A
HUMAN CLINICAL TRIAL IN DENGUE FEVER
Source text for Eikon: ID:nASX3622QP
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic